NKTR – nektar therapeutics (US:NASDAQ)

News

Nektar Therapeutics (NKTR): A Bull Case Theory [Yahoo! Finance]
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics (NASDAQ:NKTR) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $118.00 price target on the stock.
An immune drug developer raises $50M to finance its eczema drug testing [Yahoo! Finance]
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com